Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 2/20 | 0.54 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.51 |
| ▸ | USP7 | Q93009 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | FYN | P06241 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29857960 | 1.00 | MAP4K4 (0.54) | MAP4K4LRRK2USP7HTTALDH1A1 | |
| SCHEMBL12489163 | 0.85 | USP7 (0.53) | MAP4K4USP7HTTALDH1A1MAPT | |
| SCHEMBL2228665 | 0.84 | USP7 (0.71) | MAP4K4USP7HTTKMT2AFYN | |
| SCHEMBL12518227 | 0.83 | CYP2A6 (0.62) | MAP4K4LRRK2USP7KMT2AFYN | |
| SCHEMBL2222921 | 0.83 | USP7 (0.51) | MAP4K4LRRK2USP7HTTKMT2A | |
| SCHEMBL15359055 | 0.81 | USP7 (0.60) | MAP4K4USP7HTTMAPTSMN1; SMN2 | |
| SCHEMBL29857982 | 0.81 | ADORA1 (0.49) | MAP4K4LRRK2USP7HTTALDH1A1 | |
| SCHEMBL12516853 | 0.81 | ADORA1 (0.49) | MAP4K4LRRK2USP7HTTALDH1A1 | |
| SCHEMBL26916746 | 0.80 | FYN (0.53) | MAP4K4USP7HTTMAPTMAPK1 | |
| SCHEMBL29582823 | 0.80 | FYN (0.53) | MAP4K4USP7HTTMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174683-A1 | MAP4K1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-30 | — | — | US | disclosed |
| EP-4288437-A1 | MAP4K1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2023-12-13 | — | — | EP | disclosed |
| WO-2022167627-A1 | MAP4K1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-08-11 | — | — | WO | disclosed |
| US-9024033-B2 | Anti-malarial agents | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2015-05-05 | — | — | US | disclosed |
| US-20120295905-A1 | NEW ANTI-MALARIAL AGENTS | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174683-A1 | MAP4K1 INHIBITORS | MAP3K4, MAP4K4, MAP4K1 | MAP4K4 2/4885LRRK2 309/4885USP7 4285/4885 |
| US-20120295905-A1 | NEW ANTI-MALARIAL AGENTS | QDPR, DHFR, ITPA | MAP4K4 1556/4885LRRK2 4093/4885USP7 4381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.